- For Print
- May 3, 2022
爱豆传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that based on the impact of National Coverage Determination (NCD) for the anti-amyloid-beta antibody aducanumab (product name in the U.S.: ADUHELM) issued by the U.S. Centers for Medicare & Medicaid Services’ (CMS) on April 7, 2022 and other factors, Eisai has revised its consolidated financial forecasts for the fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022) previously announced on November 1, 2021, as follows.
1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2022 (April 1, 2021 to March 31, 2022)
(Unit: Millions of yen, unless otherwise noted.)
*You can scroll to the left or right here
| Revenue | Operating
profit |
Profit before
income taxes |
Profit for
the period |
Profit attributable to owners of the parent | Basic
earnings per share |
|
| Previously announced forecast (A)
(November 1, 2021) |
730,000 | 78,000 | 78,500 | 61,000 | 60,500 | 211.00 yen |
| Currently revised forecast (B) | 756,000 | 53,500 | 54,500 | 45,500 | 48,000 | 167.30 yen |
| Change in amount (B - A) | 26,000 | -24,500 | -24,000 | -15,500 | -12,500 | |
| Percentage of change (%) | 3.6% | -31.4% | -30.6% | -25.4% | -20.7% | |
| (Reference) Business results for the fiscal year ended March 31, 2021 | 645,952 | 51,766 | 52,551 | 42,483 | 42,119 | 146.95 yen |
2. Reason for revision of the consolidated financial forecasts
Revenue is estimated to be \756.0 billion, up \26.0 billion from the previously announced forecasts, based on product performance and foreign exchange trends.
Receiving Biogen Inc.’s updated demand forecast for aducanumab based on the NCD by CMS, Eisai will record an impairment loss of \8.0 billion in cost of sales after reevaluating sales rights of aducanumab recorded by Eisai as well as \16.5 billion in SG&A expenses as Eisai’s share of the write-down of inventory recorded by Biogen Inc. As a result, operating profit is estimated to be \53.5 billion, down \24.5 billion from the previously announced forecast. Accordingly, profit attributable to owners of the parent is expected to be \48.0 billion, down \12.5 billion from the previously announced forecast. There are no changes to the total dividend for the fiscal year which is set at ¥160 per share (same amount as the previous fiscal year) with the fiscal year-end dividend is planned to be ¥80 per share.
銆赌銆赌銆赌銆赌
-
*Please note that the above-mentioned forecasts were made based on information available as of May 3, 2022. Actual results will be disclosed in the earnings announcement on May 13, 2022.
Media Inquiries:
Public Relations Department,
爱豆传媒.
+81-(0)3-3817-5120